Health Condition 1: M109- Gout, unspecified
Conditions
Interventions
Intervention1: Habb-e-Chobchini and Dimad Muhallil: Habb-e-Chobchini orally 500mg twice daily for 56 days and Dimad Muhallil topically once in a day for 56 days
Control Intervention1: Placebo Dimad a
Sponsors
Central Council for Research in Unani Medicine New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: Patients aged between 18-65 years of any gender Patients with uric acid level more than 7 mg/dl and less than 9.5 mg/dl Patients having capacity and willingness to give consent and complete trial documentation
Exclusion criteria
Exclusion criteria: Patients below 18 years and above 65 years Patients who are known cases of Renal, Cardiac, Liver and Pulmonary diseases Pregnant and Lactating females Patient with uncontrolled Hypertension (SBP more than 140 mm Hg, DBP more than 90 mm Hg) Patients with uncontrolled Diabetes Mellitus (RBS more than the normal range, in patients on Insulin therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum uric acidTimepoint: 56 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in subjective parameters along with improvement in Quality of life Reduction in CRP and ESR level from baseline to the end of the treatmentTimepoint: 56 days | — |
Countries
India
Contacts
Public ContactFarooqui Shazia Parveen Barkat Ali
Regional Research Institute of Unani Medicine Chennai
Outcome results
None listed